BIOX Valuation

Bioceres Crop Solutions Corp

Add to Watchlist

Advanced Chart

3.100

-0.22(-6.627%)1D

Overview
Forecast
Valuation
Earnings

BIOX Relative Valuation

BIOX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BIOX is overvalued; if below, it's undervalued.

Historical Valuation

Bioceres Crop Solutions Corp (BIOX) is now in the Fair zone, suggesting that its current forward PE ratio of 32.63 is considered Fairly compared with the five-year average of 27.72. The fair price of Bioceres Crop Solutions Corp (BIOX) is between 1.13 to 3.86 according to relative valuation methord.

Relative Value

Fair Zone

1.13-3.86

Current Price：3.10

Fair

32.63

Trailing

Forward

7.11

EV/EBITDA

Bioceres Crop Solutions Corp. (BIOX) has a current EV/EBITDA of 7.11. The 5-year average EV/EBITDA is 9.98. The thresholds are as follows: Strongly Undervalued below 5.58, Undervalued between 5.58 and 7.78, Fairly Valued between 12.17 and 7.78, Overvalued between 12.17 and 14.37, and Strongly Overvalued above 14.37. The current Forward EV/EBITDA of 7.11 falls within the Undervalued range.

12.28

EV/EBIT

Bioceres Crop Solutions Corp. (BIOX) has a current EV/EBIT of 12.28. The 5-year average EV/EBIT is 13.53. The thresholds are as follows: Strongly Undervalued below 6.33, Undervalued between 6.33 and 9.93, Fairly Valued between 17.13 and 9.93, Overvalued between 17.13 and 20.73, and Strongly Overvalued above 20.73. The current Forward EV/EBIT of 12.28 falls within the Historic Trend Line -Fairly Valued range.

0.48

Bioceres Crop Solutions Corp. (BIOX) has a current PS of 0.48. The 5-year average PS is 1.50. The thresholds are as follows: Strongly Undervalued below 0.53, Undervalued between 0.53 and 1.01, Fairly Valued between 1.98 and 1.01, Overvalued between 1.98 and 2.47, and Strongly Overvalued above 2.47. The current Forward PS of 0.48 falls within the Strongly Undervalued range.

3.25

P/OCF

Bioceres Crop Solutions Corp. (BIOX) has a current P/OCF of 3.25. The 5-year average P/OCF is 15.26. The thresholds are as follows: Strongly Undervalued below -56.02, Undervalued between -56.02 and -20.38, Fairly Valued between 50.90 and -20.38, Overvalued between 50.90 and 86.55, and Strongly Overvalued above 86.55. The current Forward P/OCF of 3.25 falls within the Historic Trend Line -Fairly Valued range.

5.07

P/FCF

Bioceres Crop Solutions Corp. (BIOX) has a current P/FCF of 5.07. The 5-year average P/FCF is 39.69. The thresholds are as follows: Strongly Undervalued below -188.07, Undervalued between -188.07 and -74.19, Fairly Valued between 153.57 and -74.19, Overvalued between 153.57 and 267.45, and Strongly Overvalued above 267.45. The current Forward P/FCF of 5.07 falls within the Historic Trend Line -Fairly Valued range.

Bioceres Crop Solutions Corp (BIOX) has a current Price-to-Book (P/B) ratio of 0.63. Compared to its 3-year average P/B ratio of 2.23 , the current P/B ratio is approximately -71.74% higher. Relative to its 5-year average P/B ratio of 3.60, the current P/B ratio is about -82.50% higher. Bioceres Crop Solutions Corp (BIOX) has a Forward Free Cash Flow (FCF) yield of approximately 20.15%. Compared to its 3-year average FCF yield of 2.33%, the current FCF yield is approximately 766.04% lower. Relative to its 5-year average FCF yield of 0.60% , the current FCF yield is about 3271.18% lower.

0.63

P/B

Median3y

2.23

Median5y

3.60

20.15

FCF Yield

Median3y

2.33

Median5y

0.60

Competitors Valuation Multiple

The average P/S ratio for BIOX's competitors is 1.39, providing a benchmark for relative valuation. Bioceres Crop Solutions Corp Corp (BIOX) exhibits a P/S ratio of 0.48, which is -65.26% above the industry average. Given its robust revenue growth of -29.09%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

BIOX.O

Bioceres Crop Solutions Corp

American Vanguard Corp

Snow Lake Resources Ltd

Performance Decomposition

Market capitalization of BIOX decreased by 70.86% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -11.86 to -21.49.

The secondary factor is the Revenue Growth, contributed -29.09%to the performance.

Overall, the performance of BIOX in the past 1 year is driven by P/E Change. Which is more unsustainable.

-29.09%

84.04M → 59.60M

Revenue Growth

-122.96%

11.63 → -2.67

Margin Expansion

81.19%

-11.86 → -21.49

P/E Change

-70.86%